Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

726
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
726
Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Future oncology (London, England)·2026
Same author

Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.

International journal of molecular sciences·2026
Same author

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Blood cancer journal·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026
Same author

Autologous stem cell transplantation for newly diagnosed multiple myeloma - real-world data from 2,149 Czech patients.

Haematologica·2026

Related Experiment Video

Updated: May 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K

High-risk multiple myeloma: different definitions, different outcomes?

Helena Paszekova1, Fedor Kryukov1, Lenka Kubiczkova2

  • 1Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Clinical Lymphoma, Myeloma & Leukemia
|November 15, 2013
PubMed
Summary

Identifying early high-risk multiple myeloma (MM) is crucial for patient outcomes. This review compares methods for early detection of high-risk MM, addressing prognosis and treatment challenges.

Keywords:
CytogeneticsGEPHigh-risk diseaseMGUSMultiple myelomaPrognosis

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Related Experiment Videos

Last Updated: May 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Area of Science:

  • Hematology
  • Oncology
  • Cancer Research

Background:

  • Multiple myeloma (MM) is a plasma cell malignancy that, while manageable, frequently relapses.
  • Early relapse (10-15% of patients) is associated with poor prognosis and outcomes.
  • Current methods for identifying high-risk MM patients lack a universally accepted definition.

Purpose of the Study:

  • To review and compare current approaches for the early identification of high-risk multiple myeloma.
  • To analyze the strengths and weaknesses of various diagnostic strategies.
  • To contribute to a clearer definition and management of high-risk MM.

Main Methods:

  • Review of existing literature on cytogenetic and molecular biology techniques for MM risk stratification.
  • Comparative analysis of different diagnostic markers and their clinical utility.
  • Discussion of the limitations and advantages of current risk assessment tools.

Main Results:

  • Multiple cytogenetic and molecular markers are used to identify high-risk MM patients.
  • No single definition of high-risk MM is universally accepted, leading to variability in patient management.
  • Existing methods show promise but require further validation and standardization.

Conclusions:

  • Accurate early identification of high-risk MM is essential for improving patient survival and treatment strategies.
  • A standardized definition and validated methods for high-risk MM are needed.
  • Further research should focus on refining risk stratification tools for better MM management.